GenieUs Genomics

At GenieUs, we recognize ALS as a pressing challenge with a high societal cost. With over 70% of ALS patients lacking a known molecular basis, our mission is to unveil the mysteries of this complex disease. We leverage cutting-edge genomics to provide robust in silico genetic understanding through our groundbreaking platform, the Deep integrated Genomic Analysis Platform - DiGAPTM. This depth of patient genomic profiling will create valuable opportunities for the biopharma industry to develop precision diagnostic and therapeutic solutions for ALS patients. The DiGAPTM Deep Insight Report will provide clinicians with valuable insights to guide their therapeutic decisions. GenieUs is uniquely positioned to transform the ALS landscape. Were not just pioneers; were strategists ready to capitalize on the commercial potential of our innovative solutions. Our commitment is to reshape the narrative around ALS and make a lasting impact on patient lives